Rystiggo MG denied as not FDA-approved for this use by Cigna?

Cigna's specific coverage criteria for rystiggo mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rystiggo (rozanolixizumab-noli) as "Not FDA-Approved" — and Why You Can Appeal

A denial of Rystiggo as "not FDA-approved" is one of the most factually contestable denial types because Rystiggo (rozanolixizumab-noli) received FDA approval for use in adults with generalized myasthenia gravis who are anti-AChR or anti-MuSK antibody positive. When Cigna issues this denial, one of several things is typically happening: the plan's drug database has not yet updated to reflect recent approvals; the reviewer is applying the denial to a specific patient subgroup or off-label use; or there is a coding or documentation error in the claim. Each of these scenarios has a clear path to reversal.

## Your Appeal Rights

Under ACA Section 2719, non-grandfathered plans must provide independent external review after internal appeals. ERISA Section 503 guarantees a full-and-fair review with written reasoning for any continued denial. External reviewers apply standard medical evidence criteria and are not bound by a plan's internal drug list or reviewer conclusions — they will consider the FDA approval record directly. If your gMG is severe, unstable, or in crisis, expedited appeal is available. The external review window generally extends roughly four months after internal remedies are exhausted.

## The Appeal Process and Timeline

1. Verify the claim coding: confirm that the drug name, NDC, and diagnosis codes on the claim are accurate before filing the appeal — errors here can generate automatic denials that have nothing to do with clinical appropriateness. 2. Request the denial in writing — it must specify which FDA approval criterion was not met and cite the plan provision used. 3. File a first-level internal appeal with FDA approval documentation attached, within the timeframe on the denial (often 180 days). 4. If denied, proceed to external review, where the FDA's public approval record is determinative. 5. File a complaint with your state insurance commissioner if Cigna maintains a "not FDA-approved" position in the face of the public approval record.

## Documentation to Gather

• FDA approval documentation: the FDA's official approval letter and the drug's current prescribing label, available on FDA.gov, confirming approval of rozanolixizumab-noli (Rystiggo) for gMG in the relevant patient population.
• Diagnosis and antibody status: records confirming gMG diagnosis and anti-AChR or anti-MuSK antibody positivity — to show the patient falls within the FDA-labeled indication.
• Claim documentation review: verify the prescription, NDC number, and diagnosis codes submitted to Cigna are accurate and consistent with the labeled indication.
• Neurologist letter: a brief letter from the treating neurologist confirming the patient's diagnosis, antibody status, and that Rystiggo is being prescribed within its FDA-approved indication.

## Criteria-Mapping Structure

Obtain Cigna's published coverage policy or medical policy for Rystiggo or FcRn inhibitors in gMG and locate the specific language used to classify the drug. If the policy pre-dates the FDA approval or has not been updated, note the discrepancy explicitly in your appeal letter — citing the FDA approval date — and argue that the policy must be applied consistent with current regulatory status. A "not FDA-approved" denial for an approved drug used within label is a straightforward reversal candidate at external review.